Cargando…
Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to an...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631249/ https://www.ncbi.nlm.nih.gov/pubmed/35670329 http://dx.doi.org/10.2340/actadv.v102.678 |
_version_ | 1784823776578371584 |
---|---|
author | MUTO, Yusuke KAMBAYASHI, Yumi KATO, Hiroshi FUKUSHIMA, Satoshi ITO, Takamichi MAEKAWA, Takeo FUJISAWA, Yasuhiro YOSHINO, Koji UCHI, Hiroshi MATSUSHITA, Shigeto YAMAMOTO, Yuki AMAGAI, Ryo OHUCHI, Kentaro HASHIMOTO, Akira FUJIMURA, Taku |
author_facet | MUTO, Yusuke KAMBAYASHI, Yumi KATO, Hiroshi FUKUSHIMA, Satoshi ITO, Takamichi MAEKAWA, Takeo FUJISAWA, Yasuhiro YOSHINO, Koji UCHI, Hiroshi MATSUSHITA, Shigeto YAMAMOTO, Yuki AMAGAI, Ryo OHUCHI, Kentaro HASHIMOTO, Akira FUJIMURA, Taku |
author_sort | MUTO, Yusuke |
collection | PubMed |
description | Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types. |
format | Online Article Text |
id | pubmed-9631249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-96312492022-11-17 Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases MUTO, Yusuke KAMBAYASHI, Yumi KATO, Hiroshi FUKUSHIMA, Satoshi ITO, Takamichi MAEKAWA, Takeo FUJISAWA, Yasuhiro YOSHINO, Koji UCHI, Hiroshi MATSUSHITA, Shigeto YAMAMOTO, Yuki AMAGAI, Ryo OHUCHI, Kentaro HASHIMOTO, Akira FUJIMURA, Taku Acta Derm Venereol Original Article Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types. Society for Publication of Acta Dermato-Venereologica 2022-08-11 /pmc/articles/PMC9631249/ /pubmed/35670329 http://dx.doi.org/10.2340/actadv.v102.678 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Original Article MUTO, Yusuke KAMBAYASHI, Yumi KATO, Hiroshi FUKUSHIMA, Satoshi ITO, Takamichi MAEKAWA, Takeo FUJISAWA, Yasuhiro YOSHINO, Koji UCHI, Hiroshi MATSUSHITA, Shigeto YAMAMOTO, Yuki AMAGAI, Ryo OHUCHI, Kentaro HASHIMOTO, Akira FUJIMURA, Taku Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title | Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title_full | Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title_fullStr | Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title_full_unstemmed | Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title_short | Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases |
title_sort | adjuvant anti-pd-1 antibody therapy for advanced melanoma: a multicentre study of 78 japanese cases |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631249/ https://www.ncbi.nlm.nih.gov/pubmed/35670329 http://dx.doi.org/10.2340/actadv.v102.678 |
work_keys_str_mv | AT mutoyusuke adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT kambayashiyumi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT katohiroshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT fukushimasatoshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT itotakamichi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT maekawatakeo adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT fujisawayasuhiro adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT yoshinokoji adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT uchihiroshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT matsushitashigeto adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT yamamotoyuki adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT amagairyo adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT ohuchikentaro adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT hashimotoakira adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases AT fujimurataku adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases |